Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Adempas (riociguat by Quarter
Adempas (riociguat — direct Merck territory sales) — Worldwide reported growth YoY (%) (%)
Merck Adempas (riociguat: -2.0% in Q2 2026, down 12.0 pts from a year earlier.
Latest, Q2 2026
-2.0%
Period ended Jun 30, 2026
Change on a year earlier
-12.0 pts
10.0% in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below
Where the Q2 2026 figure comes from
“|| Adempas (6) | 78 | 78 | 156 | 68 | 80 | 147 | 82 | 83 | 312 | -2 | -4 | 6 | 1”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Adempas (riociguat (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-adempas-direct-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.